Request Trial
bayer-sign
15 October 2013Asia

Bayer takes another swipe at Nexavar compulsory licence

Bayer has appealed against the Indian Intellectual Property Appellate Board (IPAB)’s compulsory licence (CL) order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Novo Nordisk ramps up semaglutide defence as generics lurk
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
Asia
Novo Nordisk India strategy suffers semaglutide patent setback
4 December 2025   The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.
Asia
WIPR Rankings reveals the go-to firms and attorneys for China patent work
7 November 2025   Sister title WIPR’s China Patent Rankings detail the firms and individuals most capable of handling patent matters in the country, from litigators with winning streaks to global strategists.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

More features

PTAB year in review: A shifting landscape and outlook for 2026
UPC: A review of 2025 and what to expect in 2026
Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025
Edwards v Meril: Behind the UPC’s landmark medtech showdown
5 ways the USPTO director is changing US innovation
EU unveils sweeping pharma, biotech, and medical device reforms
Mirum targets generics in quartet of suits over liver treatment